<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_H9qFzkN">Cost-effectiveness of digital therapeutics for essential hypertension</title>
				<funder ref="#_JBTyEdK">
					<orgName type="full">CureApp Inc. (Tokyo, Japan)</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© The Author(s) 2022. This article is published with open access</p>
				</availability>
				<date type="published" when="2022-06-20">20 June 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Akihiro</forename><surname>Nomura</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Innovative Clinical Research Center , Kanazawa University , Kanazawa , Japan</note>
								<orgName type="department">Innovative Clinical Research Center</orgName>
								<orgName type="institution">Kanazawa University</orgName>
								<address>
									<settlement>Kanazawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Biomedical Informatics , CureApp Institute , Karuizawa , Japan</note>
								<orgName type="department">Department of Biomedical Informatics</orgName>
								<orgName type="institution">CureApp Institute</orgName>
								<address>
									<settlement>Karuizawa</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tomoyuki</forename><surname>Tanigawa</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> CureApp, Inc. , Tokyo , Japan</note>
								<orgName type="institution">CureApp, Inc</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kazuomi</forename><surname>Kario</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Division of Cardiovascular Medicine , Department of Medicine , Jichi Medical University School of Medicine , Tochigi , Japan</note>
								<orgName type="department" key="dep1">Division of Cardiovascular Medicine</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Jichi Medical University School of Medicine</orgName>
								<address>
									<settlement>Tochigi</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ataru</forename><surname>Igarashi</surname></persName>
							<email>atarui1@mac.com</email>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Unit of Public Health and Preventive Medicine , Yokohama City University School of Medicine , Yokohama , Japan</note>
								<orgName type="department">Unit of Public Health and Preventive Medicine</orgName>
								<orgName type="institution">Yokohama City University School of Medicine</orgName>
								<address>
									<settlement>Yokohama</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> Department of Health Economics &amp; Outcomes Research , Graduate School of Pharmaceutical Sciences , Faculty of Pharmaceutical Sciences , The University of Tokyo , Tokyo , Japan</note>
								<orgName type="department" key="dep1">Department of Health Economics &amp; Outcomes Research</orgName>
								<orgName type="department" key="dep2">Graduate School of Pharmaceutical Sciences</orgName>
								<orgName type="department" key="dep3">Faculty of Pharmaceutical Sciences</orgName>
								<orgName type="institution">The University of Tokyo</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_vcDuDGM">Cost-effectiveness of digital therapeutics for essential hypertension</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-06-20">20 June 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">84F71798C57F131CB75FED376CD1D115</idno>
					<idno type="DOI">10.1038/s41440-022-00952-x</idno>
					<note type="submission">Received: 15 March 2022 / Revised: 19 April 2022 / Accepted: 26 April 2022 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T07:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_SeVUZ7a">Essential hypertension</term>
					<term xml:id="_9KUsRzs">Digital therapeutics</term>
					<term xml:id="_FgtUkkN">Cost-effectiveness</term>
					<term xml:id="_YFQ4fRb">Lifestyle modification</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_6kpDpCX"><p xml:id="_vdq6A4j"><s xml:id="_N6ByDhu">Hypertension increases the risk of cardiovascular and other diseases.</s><s xml:id="_E9hnYpb">Lifestyle modification is a significant component of nonpharmacological treatments for hypertension.</s><s xml:id="_wBcNbsv">We previously reported the clinical efficacy of digital therapeutics (DTx) in the HERB-DH1 trial.</s><s xml:id="_nZrHeJx">However, there is still a lack of cost-effectiveness assessments evaluating the impact of prescription DTx.</s><s xml:id="_zzwWA7M">This study aimed to analyze the cost-effectiveness of using prescription DTx in treating hypertension.</s><s xml:id="_5reFHTe">We developed a monthly cycle Markov model and conducted Monte Carlo simulations using the HERB-DH1 trial data to investigate qualityadjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU), comparing DTx + TAU and TAU-only groups with a lifetime horizon.</s><s xml:id="_cpBpt67">The model inputs were obtained from the HERB-DH1 trial, published or publicly available data, and expert assumptions.</s><s xml:id="_jMQvy34">The incremental costeffectiveness ratio (ICER) per QALY was used as the benchmark for cost-effectiveness.</s><s xml:id="_YQXd27B">We performed probabilistic sensitivity analyses (PSAs) using the Monte Carlo simulation with two million sets.</s><s xml:id="_4r7DpdG">The DTx + TAU strategy produced 18.778 QALYs and was associated with ¥3,924,075 ($34,122) expected costs, compared with 18.686 QALYs and  ¥3,813,358 ($33,160)  generated by the TAU-only strategy over a lifetime horizon, resulting in an ICER of ¥1,199,880 ($10,434)/QALY gained for DTx + TAU.</s><s xml:id="_mUE7KH6">The monthly cost and attrition rate of DTx for hypertension have a significant impact on ICERs.</s><s xml:id="_a5a2Pj6">In the PSA, the probability of the DTx arm being a cost-effective option was 87.8% at a threshold value of ¥5 million ($43,478)/QALY gained.</s><s xml:id="_hJE9q99">In conclusion, the DTx + TAU strategy was more cost-effective than the TAU-only strategy.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2dEMhCj">Introduction</head><p xml:id="_vpSzgEE"><s xml:id="_dyXEUXB">Hypertension or elevated blood pressure (BP) is a serious health condition that significantly increases the risks for cardiovascular diseases (CVDs), heart failure (HF), atrial fibrillation (AFib), renal dysfunction, and other disorders <ref type="bibr" target="#b0">[1]</ref>.</s><s xml:id="_NV4B2MM">Hypertension affects 1.28 billion people and is a leading modifiable risk factor for mortality worldwide <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s xml:id="_ejjktx4">In Japan, there are more than 43 million patients with hypertension, with one of the highest prevalence rates among the Organization for Economic Co-operation and Development countries <ref type="bibr">[3]</ref>.</s><s xml:id="_gKtBSGc">In total, 50% of all CVD deaths, 59% of coronary artery disease (CAD) deaths, and 52% of stroke deaths are attributed to hypertension <ref type="bibr" target="#b2">[4]</ref>.</s><s xml:id="_FkSF32D">Additionally, the total medical cost of these CVDs has reached nearly $100 billion in Japan <ref type="bibr" target="#b3">[5]</ref>.</s><s xml:id="_czGVH58">Therefore, managing hypertension is one of the most critical factors in preventing CVDs and reducing medical costs in Japan.</s><s xml:id="_TNT6cEq">For this purpose, Health Japan 21 (the second edition) aims to reduce the average systolic BP (SBP) of the Japanese population by 4 mmHg within 10 years by raising awareness and promoting lifestyle modification including consuming a healthy diet, increasing physical activity, and reducing alcohol consumption at the national level <ref type="bibr" target="#b4">[6]</ref>.</s></p><p xml:id="_9MDxpjn"><s xml:id="_bbgEKeg">Lifestyle modification is a major component of nonpharmacological treatment for hypertension and is as essential as antihypertensive pharmacological treatment <ref type="bibr" target="#b5">[7]</ref>.</s><s xml:id="_Zr4ZvPU">In principle, hypertensive patients at low risk for CVD should first modify their lifestyle, and antihypertensive drug therapy should be initiated at an appropriate time according to the patients' future CVD risks.</s><s xml:id="_NHrXTt9">Lifestyle modification plays a vital role in lowering blood pressure because of its antihypertensive and synergistic effects along with antihypertensive drugs <ref type="bibr" target="#b6">[8,</ref><ref type="bibr" target="#b7">9]</ref>.</s><s xml:id="_2sBHnC9">However, the physician's limited outpatient time is insufficient to provide guideline-based hypertension management, including lifestyle modification suited for each patient's diverse lifestyle <ref type="bibr" target="#b8">[10]</ref>.</s><s xml:id="_C8nh2WS">As a result, lifestyle modification has not achieved its full effect in reducing BP.</s></p><p xml:id="_n3zkbaN"><s xml:id="_pvM7w9x">To maximize the potential treatment effect of lifestyle modification for hypertension, we developed a prescription digital therapeutics (DTx) for hypertension, the HERB system <ref type="bibr" target="#b9">[11]</ref>.</s><s xml:id="_sEMAsG7">The HERB system consists of a HERB Mobile smartphone app for patients and web-based patient management software for primary doctors <ref type="bibr" target="#b9">[11]</ref>.</s><s xml:id="_nQYVrFw">We previously reported the HERB-DH1 phase III randomized controlled trial (RCT) results of DTx for essential hypertension.</s><s xml:id="_zkYFwCK">In this trial, we randomly assigned 390 essential hypertension patients aged ≤65 years who were not taking antihypertensive medication to the DTx intervention group or the control group.</s><s xml:id="_eK9346X">The results showed that the primary outcome of the mean reduction in 24-h SBP from baseline to 12 weeks was significantly larger in the DTx intervention group than in the control group <ref type="bibr" target="#b10">[12]</ref>.</s></p><p xml:id="_KeqFkYb"><s xml:id="_pCnpedM">Although the HERB-DH1 trial demonstrated the clinical efficacy of DTx, there is still a lack of cost-effectiveness assessments evaluating the impact of the prescription DTx for hypertension on health care costs along with clinical efficacy.</s><s xml:id="_nukVwPv">The cost-effectiveness of DTx for opioid use disorder or that for low back pain was recently evaluated using RCT results <ref type="bibr" target="#b11">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref>.</s><s xml:id="_9a6GUrm">However, no study has assessed the cost-effectiveness of prescription DTx for hypertension using RCT data.</s><s xml:id="_zCB4W9K">Exploring the appropriate DTx pricing determined by cost-effectiveness analysis is crucial in countries including Japan, whose DTx costs could be reimbursed by public health insurance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_s4t3kUJ">Graphical Abstract</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7uJ35Kp">Cost-effectiveness of DTx for hypertension</head><p xml:id="_jYH4Wtr"><s xml:id="_2vmkuN7">Monthly cost of DTx (5000 to 20000) DTx attrition rate every 6 months</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rsbKXbf">Minimum value Maximum value</head><p xml:id="_4ppEJpf"><s xml:id="_vMBD3Ff">The monthly cost and attrition rate of DTx for hypertension have a significant impact on ICERs.</s><s xml:id="_XKVUs29">Here, we aimed to analyze the cost-effectiveness of using prescription DTx in treating hypertension using results from the HERB-DH1 phase III RCT.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3C3b3j8">Methods</head><p xml:id="_Ud7fKEH"><s xml:id="_qajhvdT">We developed an economic model to assess the cost and effectiveness of DTx for essential hypertension.</s><s xml:id="_Z9gjmgu">The model investigated quality-adjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU) (DTx + TAU) vs. TAU only with a lifetime horizon and a 1-month cycle length.</s><s xml:id="_NUBjZK4">We constructed the model from the perspective of a public healthcare payer.</s><s xml:id="_SbBnKTu">We compared the cost-effectiveness of DTx + TAU with TAU alone for the treatment of CAD, stroke, HF, and AFib.</s><s xml:id="_np86BKJ">We used the parameters of the HERB-DH1 phase III clinical trial <ref type="bibr" target="#b10">[12]</ref> as inputs.</s><s xml:id="_BqkYcQG">The HERB-DH1 trial is an open-label RCT of HERB prescription DTx in 390 patients with essential hypertension.</s><s xml:id="_BH97UHV">At 12 weeks, the DTx + TAU intervention group exhibited a significant reduction in SBP compared with the TAU-only control group (-10.6 mmHg in the DTx + TAU group vs. -6.2</s><s xml:id="_Uyzc226">mmHg in the TAU-only control group by a home BP measurement).</s><s xml:id="_VX55jTB">The present study evaluated outcomes as the incremental cost-effectiveness ratio (ICER) per QALY gained.</s><s xml:id="_kHN46NH">The model inputs were obtained from the HERB-DH1 trial data, published academic papers, publicly available data, and expert assumptions.</s><s xml:id="_NEqpXZJ">We conducted the analyses according to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement and the Ethics Guidelines for Medical and Biological Research Involving Human Subjects in Japan.</s><s xml:id="_yV7Vb6H">The authors have the right to publish, regardless of the outcome.</s><s xml:id="_4vC9rKd">The Institutional Review Board of Kanazawa University, Japan approved the study protocol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xwGr5et">Model structure and clinical pathway</head><p xml:id="_J6GSgyv"><s xml:id="_fKVKhVg">We developed a monthly cycle Markov model and conducted Monte Carlo simulations to estimate the efficacy of DTx + TAU (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_KEqRJyf">A Markov model is a stochastic process that transitions from one state to another, can be implemented from robust to model medical environments and addresses problems affecting stochastic and sequential decisions over time <ref type="bibr" target="#b14">[16]</ref>.</s><s xml:id="_78c5uty">The limitation of the pure Markov model was its memoryless property; the model cannot distinguish between those who never experienced any complication and those who did and recovered (surviving in the chronic phase).</s><s xml:id="_5UTN67Q">Under the Monte Carlo simulation, each simulated patient enters the Markov model, allowing one's entire movement to be captured.</s><s xml:id="_aspwGrc">In this model, we can assign different costs and QALYs for those with/without experience of specific complications, even if they remained in the same health state.</s><s xml:id="_234v544">Moreover, using Monte Carlo simulation, we could individually simulate patient characteristics, while only the average value could be used in the pure Markov model.</s><s xml:id="_aPjCkQ8">In this study, a Monte Carlo simulation, with 1,000,000 iterations, was performed to reflect the variation in patient characteristics, such as age and treatment effects, mainly derived from those of enrollees for the clinical trial.</s><s xml:id="_hMDaMNR">The model consisted of patients who received DTx + TAU and those who received TAU only.</s><s xml:id="_bhvyqAR">We modeled three different health statuses as follows: "stay" (healthy without any acute complications), "acute complications" (any acute complications of hypertension), and "death."</s><s xml:id="_jCkgbaX">Acute complications included CAD, stroke, HF, and AFib.</s><s xml:id="_QWzNQCy">We also considered natural deaths in the model.</s><s xml:id="_K4E6Jy2">Hypertensive patients who avoid natural death can stay in the same acute complication-free status ("stay") or experience acute complications of CAD, stroke, HF, or AFib.</s><s xml:id="_bKpqgN3">In this model, a patient with one of the acute complications must maintain the "acute complication" status or die from the complication within 12 months, then recover and switch from the "acute complication" status to the "stay" status with a postcomplication (chronic) tag [return to the "stay" status but had slightly higher mortality rates than natural deaths in patients after having either CAD, stroke, or HF].</s><s xml:id="_W3AwztF">We did not consider a patient with more than one complication within 12 months of the latest occurrence of acute complications.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7pcJ8En">Time horizon</head><p xml:id="_pRBgzCS"><s xml:id="_a7DGPSX">We set lifetime years (50 years) as the time horizon for our study.</s><s xml:id="_TXTKKHE">We also conducted scenario analyses to shift the time horizon to 20, 30, and 40 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ECXjmkC">Model population and intervention</head><p xml:id="_BtJNhjf"><s xml:id="_nVSbqg8">The study population was derived from the HERB-DH1 trial.</s><s xml:id="_uCtWuE5">The participants were grade I or II hypertensive patients without antihypertensive drug treatment, with a mean age of 52 years; 20% were female, 16% were current smokers, and the proportions of dyslipidemia and diabetes were 50 and 7%, respectively.</s><s xml:id="_cF3VdDD">The average SBP was 145 mmHg for 24-h SBP according to ambulatory BP monitoring and 148 mmHg for morning home SBP according to home BP monitoring.</s><s xml:id="_JygePZF">This model used log-normalized baseline home SBP distribution from HERB-DH1 trial data (Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_qnQk8RU">Additionally, we modeled the annual SBP increase in both groups by 0.5 mmHg from the national survey <ref type="bibr" target="#b5">[7]</ref>.</s></p><p xml:id="_VxHFSdb"><s xml:id="_T49FGVJ">The DTx + TAU group received the prescription DTx, HERB Mobile system, and lifestyle modifications to manage hypertension as recommended by the Japanese Society of Hypertension (JSH) guidelines <ref type="bibr" target="#b5">[7]</ref>.</s><s xml:id="_XqJE5Ap">The HERB Mobile system includes the HERB Mobile smartphone app and a web-based management application for health care providers.</s><s xml:id="_36KCt7w">The smartphone app retrieves each patient's baseline input data, and daily home BP measurements are transferred to the cloud server and assessed to plan a personalized lifestyle modification program to lower BP.</s><s xml:id="_JSrdQbn">In addition, primary physicians can simultaneously browse their patients' data, such as BP measurements, daily activities, or progress in the proposed program, using a webbased application <ref type="bibr" target="#b9">[11,</ref><ref type="bibr" target="#b10">12]</ref>.</s><s xml:id="_twpXSuK">The TAU-only group was also encouraged to make lifestyle modifications for hypertension based on the JSH guidelines by their primary physicians or themselves.</s><s xml:id="_h4UJnxE">We assumed that the hypertensive patients in the DTx + TAU group would have an average home SBP reduction of 10.6 mmHg, while those in the TAU-only group would have a 6.2 mmHg reduction according to a previous study <ref type="bibr" target="#b10">[12]</ref>.</s><s xml:id="_rkeWgrq">In this simulation model, we used DTx + TAU and TAU-only effect distributions derived from the HERB-DH1 trial data (Supplementary Fig. ).</s><s xml:id="_YgGFgSE">Since DTx adherence could decrease with time, we set the model such that 25% of the remaining users in the DTx + TAU group discontinued use of the DTx every 6 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_85kBj8V">Mortality and complications</head><p xml:id="_D2M4VrP"><s xml:id="_u28ECd6">We obtained the annual natural death rates from the Japan Vital Statistics for 2022 <ref type="bibr" target="#b15">[17]</ref>.</s><s xml:id="_WpSnS6y">The annual mortality and occurrence rates of each complication are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s xml:id="_Mc6N3vY">We set both acute and poststate (chronic) mortality rates for each complication <ref type="bibr" target="#b16">[18]</ref><ref type="bibr" target="#b17">[19]</ref><ref type="bibr" target="#b18">[20]</ref><ref type="bibr" target="#b19">[21]</ref><ref type="bibr" target="#b20">[22]</ref><ref type="bibr" target="#b21">[23]</ref>.</s></p><p xml:id="_AhX7sap"><s xml:id="_fDudXgz">The occurrence rates of each complication were adjusted according to BP categories (Supplementary Table) <ref type="bibr" target="#b16">[18]</ref>.</s><s xml:id="_jWfTMDk">Additionally, the annual incidence rates of CAD and stroke were calibrated according to the previously reported lifetime risks <ref type="bibr" target="#b22">[24,</ref><ref type="bibr" target="#b23">25]</ref>.</s><s xml:id="_SFWtFBE">In addition, the annual incidence rate of HF was calibrated according to patient age (hazard ratios [HRs] of 2.5, 5.0, and 10 for people in their 60 s, 70 s, and ≥80 s) <ref type="bibr" target="#b24">[26]</ref>.</s><s xml:id="_R6UGjEe">Categories of normal BP, elevated BP, grade I HT, and grade II HT were defined as home SBPs of &lt;125, 125-134, 135-144, and ≥145 mmHg, respectively <ref type="bibr" target="#b5">[7]</ref>.</s><s xml:id="_ND7Sujr">Since the cycle length of the model was 1 month, we converted the annual rates to monthly rates to input into the model.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ATrwADf">Costs</head><p xml:id="_BPVYCHX"><s xml:id="_rrFKEYu">A list of the cost data is presented in Table <ref type="table" target="#tab_0">1</ref>.</s><s xml:id="_4T5Dj9h">We performed an economic estimation from Japan's public health care payer perspective, under which only medical costs were considered.</s><s xml:id="_dJVyjHY">The costs consist of treatment and hospitalization expenses but not transportation fees or family care service costs.</s><s xml:id="_DDTpxUU">We set the monthly cost of HERB DTx at ¥10,000 ($86.96</s><s xml:id="_3jDy2z4">US: $1 US = ¥115 as of January 2022), including app purchases and subscription fees.</s><s xml:id="_6xKcAx8">The cost of each complication (CAD, stroke, HF, and AFib) was also derived from previous studies <ref type="bibr" target="#b25">[27]</ref><ref type="bibr" target="#b26">[28]</ref><ref type="bibr" target="#b27">[29]</ref><ref type="bibr" target="#b28">[30]</ref>.</s><s xml:id="_bpJrSCX">We set an annual cost reduction of 2% according to the Japanese guideline for cost-effectiveness analyses <ref type="bibr" target="#b29">[31]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_wAwrfdU">Health-related quality of life and utilities</head><p xml:id="_g4sYEJM"><s xml:id="_H7vWmvA">We derived the utility values of CAD, stroke, HF, and AFib from published studies based on the European Quality of Life-5 Dimensions Questionnaire (Table <ref type="table" target="#tab_0">1</ref>) <ref type="bibr" target="#b28">[30,</ref><ref type="bibr" target="#b30">32,</ref><ref type="bibr" target="#b31">33]</ref>.</s><s xml:id="_rWJD7Gk">We calculated QALYs by multiplying the time duration in a specific health state by the utility value associated with the state.</s><s xml:id="_nSUbB7k">Both cost and outcome were discounted at a 2% discount rate <ref type="bibr" target="#b29">[31]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8u9r8kp">Main analysis</head><p xml:id="_FAJPcu5"><s xml:id="_X5RUXyr">We calculated the ICER between DTx + TAU and TAUonly strategies over the lifetime horizon using the estimated model parameters and cost and effectiveness assumptions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_K2eQQBt">Sensitivity and scenario analyses</head><p xml:id="_QaPDHX2"><s xml:id="_yE3NF6f">We tested the impact of the uncertainties around the model parameters on the overall cost-effectiveness results using oneway deterministic and probabilistic sensitivity analyses.</s><s xml:id="_dmyZ7Bx">First, we performed one-way deterministic sensitivity analyses by changing the treatment effect, cost, and utility parameters over each range between low and high values (Table <ref type="table" target="#tab_0">1</ref> and Supplementary Table ).</s><s xml:id="_mx99UjS">Then, we conducted probabilistic sensitivity analyses to evaluate the sensitivity of the results to simultaneous variable changes using a set of two million (2000 iterations × 1000 individuals) simulated results with specific probability distributions of the input parameters.</s><s xml:id="_zguk28p">We assumed a Weibull distribution for age; log-normal distribution for initial SBP input; normal distributions for HRs of each complication according to BP grade, mortality rates, and health utilities; beta distributions for clinical event incidence rates; and gamma distributions for costs.</s><s xml:id="_d9HQVec">In addition, we drew the probability of the cost-effectiveness acceptability curve to evaluate the costeffectiveness probability at a willingness-to-pay threshold of ¥5 million ($43,478) <ref type="bibr" target="#b32">[34]</ref>.</s><s xml:id="_H4pXxvX">Additionally, we conducted two scenario analyses as follows: (#1) simulating different time horizons of 20, 30, and 40 years; and (#2) setting an alternative DTx app attrition rate of 10% every six months.</s><s xml:id="_NSrvrYp">All model The terminal condition of _stage = 600 denotes that the maximum cycle length would be 600 times.</s><s xml:id="_WsPBKaE">Given that one cycle is equal to one month, 600 iterations means that the time horizon was set to 50 years (600 months), or a lifetime.</s><s xml:id="_rbsc3dB">We set three health statuses: stay (acute complication-free status), acute complication, or death.</s><s xml:id="_vtP8WhZ">The occurrence of acute complications or death rates varies according to age, home systolic blood pressure level, and the latest acute complication history.</s><s xml:id="_44Wbf6q">Additionally, acute complication status includes four hypertension-related complications: coronary artery disease, stroke, heart failure, and atrial fibrillation</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_NYbAdZp">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sCkaU64">Main analysis</head><p xml:id="_YQyCTW5"><s xml:id="_SvSeM7P">The model predicted that the DTx + TAU strategy produced</s></p><p xml:id="_Md8qKxN"><s xml:id="_Qt9YDcz">18.778 QALYs and was associated with ¥3,924,075 ($34,122) expected costs compared to 18.686 QALYs and ¥3,813,358 ($33,160) generated by TAU-only treatment over a lifetime horizon.</s><s xml:id="_d4PfVNm">The introduction of DTx would increase costs by ¥110,717 ($962) and prolong QALYs by 0.092.</s><s xml:id="_hQMNCGq">The ICER of DTx + TAU against TAU would be ¥1,199,880 ($10,434)/ QALY gained, which was well below the hypothetical threshold value in Japan of ¥5 million/QALY gained (Table 2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jyaeqSc">Sensitivity analyses</head><p xml:id="_hGm3cnX"><s xml:id="_b7NP4wG">We conducted one-way deterministic and probabilistic sensitivity analyses.</s><s xml:id="_a3aRcTk">The results of the one-way deterministic sensitivity analyses with the tornado diagram are shown in Fig. <ref type="figure">2</ref>. The monthly cost of DTx, which ranged from ¥5,000 ($43.48)/month to ¥20,000 ($173.91)/month,</s><s xml:id="_9GFuVUS">had the largest impact on the ICER value, followed by the DTx attrition and discount rates.</s><s xml:id="_xTa4XDA">According to the one-way threshold analysis for the monthly DTx cost, the DTx + TAU arm became the dominant strategy when the cost was below ¥5,163 ($44.90) per month.</s><s xml:id="_t3eTMcw">Even the highest ICER value observed in this diagram was still below the threshold value of ¥5 million/QALY gained.</s></p><p xml:id="_VUT5hJR"><s xml:id="_XApnr6n">The results of the probabilistic sensitivity analysis are shown with incremental cost-effectiveness scatter plots (Fig. <ref type="figure">3</ref>) and a cost-effectiveness acceptability curve (Fig. <ref type="figure">4</ref>).</s><s xml:id="_AemHVmq">According to these figures, the probability of dominance (DTx less costly and more effective) and cost-effectiveness (DTx more costly and more effective, the ICER was less than ¥5 million/QALY gained) were 6.5% and 81.3%, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_PXwv6FB">Scenario analyses</head><p xml:id="_EHTC8kX"><s xml:id="_2yfe5dN">In scenario #1, by changing the simulation duration, the ICERs for the DTx + TAU treatment were inversely proportional to the extent of the time horizon (Table <ref type="table" target="#tab_2">2</ref>).</s><s xml:id="_a988n8z">In scenario #2, using an alternative DTx attrition rate of 10% every six months, ICER was reached in ¥4,330,295 ($37,655)/QALY.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RRUVxW8">Discussion</head><p xml:id="_7GnGWUv"><s xml:id="_DGACFnY">In this study, we assessed the cost-effectiveness of prescription DTx for essential hypertension, in addition to TAU, compared to the TAU-only strategy.</s><s xml:id="_DVtqrfG">We found that the ICER of the DTx + TAU strategy was ¥1,199,880 ($10,434)/QALY against the TAU-only strategy in the lifetime horizon, which was well below the threshold value of ¥5 million/QALY.</s><s xml:id="_ffhcGgy">Moreover, the probability of the cost being below the threshold value was 87.8% in the value.</s><s xml:id="_2m98N7S">The green ellipse indicates the 95% confidence area of the simulations.</s><s xml:id="_k2nERZ7">The probability rates of dominance (the area filled with light blue) and cost-effectiveness (the area filled with light green) were 6.5% and 81.3%, respectively.</s><s xml:id="_57eCPJj">Abbreviations: ICER incremental costeffectiveness ratio, JPY Japanese yen, QALY quality-adjusted life years, WTP willingness-to-pay Fig. 4 Cost-effectiveness acceptability curve in the DTx + TAU and TAU-only groups.</s><s xml:id="_UfYZrHQ">The X-axis indicates the threshold value for 1 QALY gained (we preset the threshold value as ¥5 million/QALY gained, shown as the dashed line), and the Y-axis denotes the probability of being chosen as the most cost-effective option.</s><s xml:id="_aPZdGj7">As the threshold value increases, the probability of choosing the DTx + TAU strategy (the blue curve) sharply increases, whereas that of choosing the TAU-only strategy (the red curve) decreases.</s><s xml:id="_YDYeHPB">At the intersection of the two curves, the threshold value was approximately ¥1,200,000/ QALY gained, which was sufficiently below the preset threshold of ¥5 million/QALY gained.</s><s xml:id="_dj8Yvwa">Abbreviations: DTx digital therapeutics, JPY Japanese yen, QALY quality-adjusted life years, TAU treatment as usual</s></p><p xml:id="_gzDAQMk"><s xml:id="_cdGKKfE">probabilistic sensitivity analysis.</s><s xml:id="_62RJ2Rx">This model analysis demonstrated that DTx + TAU is cost-effective for patients with hypertension.</s><s xml:id="_tQwkqcK">Several conclusions can be drawn from this study.</s><s xml:id="_caamhr5">First, this is the first study to evaluate the cost-effectiveness of DTx for patients with hypertension using the results of an RCT.</s><s xml:id="_F7XPuAZ">Nordyke et al. reported the cost-effectiveness of DTx for hypertension with person-to-person health coaching according to data from a retrospective study over a 3-year time horizon <ref type="bibr" target="#b33">[35,</ref><ref type="bibr" target="#b34">36]</ref>.</s><s xml:id="_UmtvGSU">Other than hypertension, DTx for opioid use disorder and that for low back pain also revealed cost-effectiveness in a relatively short time horizon (12 weeks to 3 years) without considering mortality rates <ref type="bibr" target="#b11">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref>.</s><s xml:id="_QZSft43">Although the time to half DTx usage rate was approximately 15 months in this model, the benefit of the BP-lowering effect persisted for more than three years, resulting in prevention of the trajectory of CVD from hypertension, left ventricular hypertrophy, and atherosclerotic events to HF and CVD deaths.</s><s xml:id="_hWrt9bc">Therefore, a longterm cost-effectiveness analysis would be valuable when considering the practical effects of DTx for chronic diseases such as hypertension.</s></p><p xml:id="_EnBt7kr"><s xml:id="_7H4pdCf">The monthly cost of DTx for hypertension had the greatest impact on ICERs in the one-way deterministic sensitivity analysis.</s><s xml:id="_TFMh5Xq">Lewkowicz et al. pointed out a similar conclusion by evaluating the cost-effectiveness of DTx for low back pain <ref type="bibr" target="#b13">[15]</ref>.</s><s xml:id="_hCABHSS">At a DTx cost of ¥5,000/month, DTx dominated conventional therapy or was a less costly and more effective option.</s><s xml:id="_b4ZwFJ2">Even when we set the cost at ¥20,000/ month, the ICER was approximately ¥3.5 million/QALY, which is still under the threshold value of ¥5 million/QALY (Fig. <ref type="figure">2</ref>).</s><s xml:id="_3wGrMKf">Recently, sacubitril/valsartan (angiotensin receptorneprilysin inhibitor), a novel antihypertensive drug, was approved for hypertension management in Japan <ref type="bibr" target="#b35">[37]</ref>, with a medication cost of ¥6,057 ($52.67) to ¥12,114 ($105.34)/</s><s xml:id="_ffV9wHp">month.</s><s xml:id="_3xxJ6jj">Thus, the DTx cost we set to approximately ¥10,000/ month as the default might be a reasonable value according to the current simulation model.</s></p><p xml:id="_GGYFK6y"><s xml:id="_WZGaGhs">The attrition rate of the DTx program is a crucial factor for cost-effectiveness.</s><s xml:id="_t8DSrke">A smartphone mHealth app usage rate attenuated over time, reporting that approximately 40% of attrition occurred from 6 months to 1 year <ref type="bibr" target="#b36">[38]</ref>.</s><s xml:id="_89VAqAn">Previous DTx studies used for cost-effectiveness analyses also used similar attrition rates <ref type="bibr" target="#b13">[15,</ref><ref type="bibr" target="#b33">35]</ref>.</s><s xml:id="_Q39vpYt">Thus, it could be reasonable to set the attrition rate to 25% for every 6 months in this model, which was approximately 15 months as time to half usage rate since the initiation of DTx.</s><s xml:id="_fhdgSPb">In another scenario, when we changed the rate to 10% (lower than the predefined 25%), the time to half exceeded approximately 40 months, and the ICER was increased to approximately ¥4.3 million/QALY in a lifetime horizon, which was close to the threshold value (Fig. <ref type="figure">2</ref>).</s><s xml:id="_MEKNhnX">Lewkowicz et al. previously reported that lowering the DTx app attrition rate was essential for cost-effectiveness in a relatively short-term (3year) horizon <ref type="bibr" target="#b13">[15]</ref>.</s><s xml:id="_hRDc4Eu">Although the model inputs and target disease were different, it might be possible that high attrition rates along with DTx actual usage duration could substantially impact DTx cost-effectiveness.</s><s xml:id="_Fg5sD9B">Achieving good cost-effectiveness for DTx might require sensitive handling to balance the appropriate DTx app usage duration with DTx costs and expected attrition rate.</s></p><p xml:id="_3haPUmz"><s xml:id="_J6QJ2CH">The degree of the gained ICER using DTx hypertension management surely depends on the degree of BP reduction by quality of the DTx app algorithm, the impact of BP reduction, and the cost of cardiovascular events in each country.</s><s xml:id="_2F6P9SA">A significant difference in home BP reduction (-4.3 mmHg of morning home SBP) was clearly found between the DTx + TAU and TAU-only groups from the previous phase III clinical trial.</s><s xml:id="_r23usJa">Notably, this TAU-only group followed the ideal guideline-driven management of hypertension, which used home BP monitoring <ref type="bibr" target="#b5">[7]</ref>.</s><s xml:id="_Qn35HS8">Compared with office BP, home BP is more closely associated with cardiovascular event risk <ref type="bibr" target="#b37">[39,</ref><ref type="bibr" target="#b38">40]</ref>.</s><s xml:id="_hBA6hwx">In addition, in Asian countries, the benefit of BP reduction is greater than that in Western countries, especially for stroke <ref type="bibr" target="#b39">[41]</ref>.</s><s xml:id="_rSFKhqS">The comparison of cost-effectiveness studies using different DTx apps in different contigs is also needed in the future.</s></p><p xml:id="_S5gpYGV"><s xml:id="_9dsC9Wb">The strength of this study is that, to our knowledge, this is the first study to evaluate the cost-effectiveness of DTx for patients with hypertension using the results from an RCT.</s><s xml:id="_DFyeEfN">Furthermore, we demonstrated that DTx + TAU is cost-effective for patients with hypertension.</s><s xml:id="_kfK2TPp">This study has some limitations.</s><s xml:id="_GCWAjmY">First, we used middle-aged, digitalfriendly grade I or II hypertensive patients who were not taking antihypertensive medication for the simulations according to previous RCT results.</s><s xml:id="_6xkdQw7">Thus, caution should be taken when applying our results to a broader population.</s><s xml:id="_wrhFaYg">Second, we modeled the DTx effect as permanent, although the effect estimates were derived from the 6-month duration of the HERB-DH1 trial results.</s><s xml:id="_er38BVp">Thus, it might be possible that the treatment effect could attenuate or diminish over time, especially six months after the intervention.</s><s xml:id="_z96tSBs">Although we set the BP reduction effects even for the TAU-only strategy and age-related annual SBP increases in both groups, this could lower the mortality and complication occurrence rates in the DTx + TAU strategy, resulting in a higher ICER than we concluded in this study.</s><s xml:id="_Sf7rdzx">Third, we did not estimate the additive effects of having multiple comorbidities in this model, which could impact lifetime ICER.</s><s xml:id="_X54PUk7">Fourth, we could not strictly assess the DTx costeffectiveness in addition to antihypertensive medications since the model patients derived from previous trials were all antihypertensive drug-naïve.</s><s xml:id="_27VM25k">Finally, we did not consider reusing DTx after finishing the initial DTx usage according to the attrition rate, which could account for additional costs for the DTx strategy.</s></p><p xml:id="_8VK2JDa"><s xml:id="_hT9r9A6">In conclusion, DTx + TAU demonstrated good costeffectiveness in hypertensive patients compared to the TAU-only strategy.</s><s xml:id="_edtQRFH">DTx cost and its attrition rate largely influence cost-effectiveness, and we need to explore the balance among the DTx application cost, app attrition rate, and effectiveness for target hypertensive patients in clinical practice.</s><s xml:id="_5VYY7Ek">DTx is generally reimbursed by Japan's national universal health insurance system.</s><s xml:id="_DrPfg6S">Thus, it is becoming increasingly essential to evaluate the cost-effectiveness of DTx, as was done in this study, to consider the appropriate value-based reimbursement pricing.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>0 - 1 ,</head><label>1</label><figDesc><div><p xml:id="_xRAsj68"><s xml:id="_rxZyHKA">000,000 Monthly cost of DTx (5000 to 20000) DTx attrition rate every 6 mo (0.25 [default] to 0.10) Discount rate (0 to 0.04) Annual SBP increase (0.39 to 0.65) Utility of Normal (0.760 to 1.000) Annual incidence rate of stroke (1.194 to 1.990) Annual incidence rate of CAD (0.345 to 0.575) ICER Minimum value Maximum value Modifier coefficient of HF incidence over 60s (0.5 to 1.5) Hazard ratio of HF for elevated BP (0.1398 to 0.0488) Hazard ratio of CAD for elevated BP (0.01 to 0.2624) Cost-effectiveness of digital therapeutics (DTx) for essential hypertension Study overview We developed a monthly cycle Markov model and conducted Monte Carlo simulations using the HERB-DH1 trial data to investigate quality-adjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU), comparing DTx+TAU and TAU-only groups with a lifetime horizon.</s><s xml:id="_kk9YnxE">Citation (Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al.</s><s xml:id="_8RqgmdW">Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial.</s><s xml:id="_tjJAbtE">Eur Heart J. 2021;42(40):4111-4122.</s><s xml:id="_QyXy3ZK">) cost-effectiveness ratio [ICER] per QALY was used as the benchmark for cost-effectiveness.)</s><s xml:id="_8nyp94v">Conclusions: The DTx+TAU strategy was more cost-effective than the TAU-only strategy.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><figDesc><div><p xml:id="_uUkSksf"><s xml:id="_Fj7RkT7">costly and MORE effective (dominant) 6.5% MORE costly but MORE effective (cost-effective, ICER&lt;JPY5Mil) 81.3%</s><s xml:id="_TghD9n8">The probability of the DTx arm being a cost-effective option gained.50000</s><s xml:id="_pgNXNCf">0</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_9XJqYNE"><s xml:id="_aqsuBW5">Fig. 1 Structure of the simulation model.</s><s xml:id="_wVs3EgH">A Decision tree.</s><s xml:id="_WwXCSFP">B Structure of the Markov model.</s><s xml:id="_ANCux2E">C Structure of the Stay (no acute complications) module.</s><s xml:id="_nz4ShbE">D Structure of the acute complications module.</s><s xml:id="_wB5PjS8">TreeAge Pro Healthcare software was used to create this simulation model.</s><s xml:id="_GZrpdvX">The blue square indicates the decision node; M in the purple circle indicates the Markov node; the green circle indicates the chance node; L in the green circle indicates the logic node; and the red triangle indicates the terminal node.The terminal condition of _stage = 600 denotes that the maximum cycle length would be 600 times.</s><s xml:id="_2fNWUFp">Given that one cycle is equal to one month, 600 iterations means that the time horizon was set to 50 years (600 months), or a lifetime.</s><s xml:id="_TwJrpR5">We set three health statuses: stay (acute complication-free status), acute complication, or death.</s><s xml:id="_K85sDGp">The occurrence of acute complications or death rates varies according to age, home systolic blood pressure level, and the latest acute complication history.</s><s xml:id="_HYGHAhU">Additionally, acute complication status includes four hypertension-related complications: coronary artery disease, stroke, heart failure, and atrial fibrillation</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 3 Fig. 4</head><label>34</label><figDesc><div><p xml:id="_ksjhVBR"><s xml:id="_t3Xg5yQ">Fig. 3 Cost-effectiveness plot.</s><s xml:id="_JhvBU79">Each dot represents one Monte Carlo simulation result of incremental QALY and cost.</s><s xml:id="_K4UT9Cv">The green plots indicate that the simulation outputs demonstrated that DTx + TAU was cost-effective in terms of ICER less than ¥5 million/QALY gained, whereas the red plots denote that the outputs did not show that DTx + TAU was cost-effective or that ICER exceeded the threshold</s></p></div></figDesc><graphic coords="8,172.78,57.68,284.09,181.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s xml:id="_cxE7yEV">Model inputsAF atrial fibrillation, BP blood pressure, CAD coronary artery disease, CI confidence interval, HF heart failure, SBP systolic blood pressure a Range for sensitivity analysis analyses were conducted using TreeAge Pro HealthCare version 2022 R1.0 (TreeAge Software, LLC, MA, USA).</s></p></div></figDesc><table><row><cell>Data</cell><cell>Input</cell><cell>Low a</cell><cell>High a</cell><cell>Source</cell></row><row><cell>Age</cell><cell>52.3 years</cell><cell>-</cell><cell>-</cell><cell>Kario [12, 40]</cell></row><row><cell>Baseline SBP</cell><cell>148 mmHg</cell><cell>-</cell><cell>-</cell><cell>Kario [12, 40]</cell></row><row><cell>Annual BP increase</cell><cell>0.5 mmHg</cell><cell>0.39</cell><cell>0.65</cell><cell>Umemura [7]</cell></row><row><cell>Annual mortality rates by complications</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Coronary artery disease</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>First 1 month after event onset</cell><cell>5.0%/month</cell><cell>0</cell><cell>5.0</cell><cell>Komiyama [19]</cell></row><row><cell>&gt;1 month (post-CAD)</cell><cell>0.98%</cell><cell>0.93</cell><cell>1.74</cell><cell>Goto [20]</cell></row><row><cell>Stroke</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>First 1 month after event onset</cell><cell>12.9% / month</cell><cell>9.7</cell><cell>16.1</cell><cell>Takashima [23]</cell></row><row><cell>&gt;1 month (post-Stroke)</cell><cell>1.29%</cell><cell>-</cell><cell>-</cell><cell>Goto [20]</cell></row><row><cell>Heart failure</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>First 12 months after event onset</cell><cell>11.5%</cell><cell>10.1</cell><cell>13.0</cell><cell>Shiraishi [21]</cell></row><row><cell>&gt;13 months (post-HF)</cell><cell>2.5%</cell><cell>-</cell><cell>-</cell><cell>Tsuji [22]</cell></row><row><cell>Atrial fibrillation</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>First 12 months after event onset</cell><cell>1.83%</cell><cell>1.28</cell><cell>2.56</cell><cell>Goto [20]</cell></row><row><cell>&gt;13 months (post-AFib)</cell><cell cols="2">Same as the natural mortality rate</cell><cell></cell><cell>-</cell></row><row><cell cols="2">Annual incidence rates of each complication among hypertension patients</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Coronary artery disease</cell><cell>0.460%</cell><cell>0.345</cell><cell>0.575</cell><cell>Kaneko [18], Turin [24]</cell></row><row><cell>Stroke</cell><cell>1.592%</cell><cell>1.194</cell><cell>1.990</cell><cell>Kaneko [18], Turin [25]</cell></row><row><cell>Heart failure</cell><cell>0.889%</cell><cell>-</cell><cell>-</cell><cell>Kaneko [18], Fujimoto [26]</cell></row><row><cell>Atrial fibrillation</cell><cell>0.232%</cell><cell>-</cell><cell>-</cell><cell>Kaneko [18]</cell></row><row><cell>Annual costs</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DTx for hypertension</cell><cell>¥120,000 ($1,043)</cell><cell>60,000</cell><cell>240,000</cell><cell>Assumption</cell></row><row><cell cols="2">Acute phase (First 12 months after event onset)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Coronary artery disease</cell><cell>¥2,156,290 ($18,750)</cell><cell>1,617,218</cell><cell>2,695,362</cell><cell>Kamae [27]</cell></row><row><cell>Stroke</cell><cell>¥1,440,107 ($12,523)</cell><cell>1,080,080</cell><cell>1,800,134</cell><cell>Kamae [27]</cell></row><row><cell>Heart failure</cell><cell>¥770,428 ($6,699)</cell><cell>577,821</cell><cell>963,035</cell><cell>Mizuno [28]</cell></row><row><cell>Atrial fibrillation</cell><cell>¥120,000 ($1,043)</cell><cell>90,000</cell><cell>150,000</cell><cell>Kamae [29]</cell></row><row><cell>Post-complication phase (&gt;12 months)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Coronary artery disease</cell><cell>¥495,600 ($4,310)</cell><cell>459,996</cell><cell>570,000</cell><cell>Kodera [30]</cell></row><row><cell>Stroke</cell><cell>¥318,387 ($2,769)</cell><cell>262,992</cell><cell>372,996</cell><cell>Kodera [30]</cell></row><row><cell>Heart failure</cell><cell>¥770,428 ($6,699)</cell><cell>577,821</cell><cell>963,035</cell><cell>Mizuno [28]</cell></row><row><cell>Atrial fibrillation</cell><cell>¥120,000 ($1,043)</cell><cell>90,000</cell><cell>150,000</cell><cell>Kamae [29]</cell></row><row><cell>Health utilities</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>0.950</cell><cell>0.760</cell><cell>1.000</cell><cell>-</cell></row><row><cell>Coronary artery disease (increment)</cell><cell>-0.180</cell><cell>-0.135</cell><cell>-0.225</cell><cell>Kodera [30]</cell></row><row><cell>Stroke (increment)</cell><cell>-0.157</cell><cell>-0.117</cell><cell>-0.196</cell><cell>Hattori [32]</cell></row><row><cell>Heart failure (increment)</cell><cell>-0.101</cell><cell>-0.076</cell><cell>-0.126</cell><cell>Clarke [33]</cell></row><row><cell>Atrial fibrillation (increment)</cell><cell>-0.000</cell><cell>-</cell><cell>-</cell><cell>Assumption</cell></row><row><cell>Death (increment)</cell><cell>-0.950</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Discount rates</cell><cell>2%</cell><cell>0</cell><cell>4</cell><cell>Shiroiwa [31]</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p xml:id="_xB4CJZt"><s xml:id="_ZMDCW4N">Cost-effectiveness of DTx for hypertension</s></p></div></figDesc><table><row><cell>Outcome</cell><cell>DTx + TAU</cell><cell>TAU-only</cell><cell>Changes</cell></row><row><cell cols="2">Lifetime horizon</cell><cell></cell><cell></cell></row><row><cell>Costs</cell><cell>¥3,924,075</cell><cell>¥3,813,358</cell><cell>¥110,717 ($9-</cell></row><row><cell></cell><cell>($34,122)</cell><cell>($33,160)</cell><cell>62)</cell></row><row><cell cols="2">QALYs 18.778</cell><cell>18.686</cell><cell>0.092</cell></row><row><cell>ICER</cell><cell cols="2">¥1,199,880 ($10,434)/QALY a</cell><cell></cell></row><row><cell cols="2">40-year time horizon</cell><cell></cell><cell></cell></row><row><cell>Costs</cell><cell>¥3,705,428</cell><cell>¥3,591,385</cell><cell>¥114,043</cell></row><row><cell cols="2">QALYs 18.483</cell><cell>18.395</cell><cell>0.089</cell></row><row><cell>ICER</cell><cell cols="2">¥1,284,159 ($11,167)/QALY</cell><cell></cell></row><row><cell cols="2">30-year time horizon</cell><cell></cell><cell></cell></row><row><cell>Costs</cell><cell>¥2,996,162</cell><cell>¥2,869,894</cell><cell>¥126,268</cell></row><row><cell cols="2">QALYs 17.195</cell><cell>17.124</cell><cell>0.071</cell></row><row><cell>ICER</cell><cell cols="2">¥1,788,344 ($15,551)/QALY</cell><cell></cell></row><row><cell cols="2">20-year time horizon</cell><cell></cell><cell></cell></row><row><cell>Costs</cell><cell>¥1,820,066</cell><cell>¥1,664,483</cell><cell>¥155,583</cell></row><row><cell cols="2">QALYs 13.939</cell><cell>13.903</cell><cell>0.037</cell></row><row><cell>ICER</cell><cell cols="2">¥4,235,677 ($36,832)/QALY</cell><cell></cell></row></table><note xml:id="_52XH8px"><p>DTx digital therapeutics, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, TAU treatment as usual a The ICER was calculated by the following numbers before rounding (the cost change: 110716.867722453 yen; and the QALY change: 0.092273268384691) Fig.2</p><p><s xml:id="_BnSJ94s">One-way sensitivity analysis results.</s><s xml:id="_9HPwbQN">Bar plots indicate the changes in values in each parameter range (minimum value in blue and maximum value in red).</s><s xml:id="_RajzGv3">The monthly cost of DTx had the largest impact on the ICER value, followed by the DTx attrition and discount rates.</s><s xml:id="_pZ6h8K8">Even the highest ICER value observed in this diagram was below the threshold of ¥5 million/QALY gained.</s><s xml:id="_5DD8YUC">Abbreviations: BP blood pressure, CAD coronary artery disease, DTx digital therapeutics, HF heart failure, ICER incremental cost-effectiveness ratio, WTP willingness-to-pay</s></p></note></figure>
		</body>
		<back>


			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_YcaYhme"><p xml:id="_nWVCKxN"><s xml:id="_8pbdkp7">Acknowledgements We would like to express our gratitude to all participants involved in this study.</s></p></div>
			</div>


			<div type="funding">
<div xml:id="_7Tnvrpy"><p xml:id="_j8FwFup"><s xml:id="_8pAUEyT">Funding The <rs type="grantNumber">HERB-DH1 RCT</rs>, the data of which were used in this study, was sponsored by <rs type="funder">CureApp Inc. (Tokyo, Japan)</rs>.</s></p></div>
<div><head xml:id="_yVb4cC6">Compliance with ethical standards</head></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_JBTyEdK">
					<idno type="grant-number">HERB-DH1 RCT</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_pMSJHPa"><p xml:id="_KqDSsYT"><s xml:id="_Y7Q3qkW">Conflict of interest CureApp Inc. has patents and distribution rights for the HERB mobile prescription DTx system.</s><s xml:id="_MtsFutv">AN, KK, and AI received consulting fees from CureApp Inc. AN was a co-founder of the CureApp Institute.</s><s xml:id="_gAAyuYJ">TT is the chief medical officer of CureApp, Inc.</s></p><p xml:id="_sdcmmZN"><s xml:id="_NtKmj9b">Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p><p xml:id="_gFwbvhs"><s xml:id="_NrVGNYp">Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</s><s xml:id="_7XH66P7">The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material.</s><s xml:id="_5U8SZMs">If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</s><s xml:id="_dWhJ7jt">To view a copy of this license, visit <ref type="url" target="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.  org/licenses/by/4.0/</ref>.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<idno type="DOI">10.1016/b978-0-323-03961-1.50098-2</idno>
		<ptr target="https://www.who.int/news-room/fact-sheets/detail/hypertension" />
		<title level="m" xml:id="_aeSKbKf">Hypertension</title>
		<imprint>
			<publisher>World Health Organization</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">World Health Organization. Hypertension. https://www.who.int/ news-room/fact-sheets/detail/hypertension.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_sBUdhnG">Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B D</forename></persName>
		</author>
		<idno type="DOI">10.1002/hon.2936/v1/review1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_j5tJ65S">Lancet</title>
		<imprint>
			<biblScope unit="volume">396</biblScope>
			<biblScope unit="page" from="1223" to="1249" />
			<date type="published" when="2019">2019. 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">G. B. D. Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223-49.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_B6aUEzZ">Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fujiyoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohkubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Miura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Nagasawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okamura</surname></persName>
		</author>
		<idno type="DOI">10.1038/hr.2012.87</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_C6mTXx5">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="947" to="953" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa SY, Okamura T, et al. Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res. 2012;35:947-53.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_Vfdxv4z">Comprehensive cost of illness of three major diseases in Japan</title>
		<author>
			<persName><forename type="first">K</forename><surname>Matsumoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hanaoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hasegawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_983tpEA">J Stroke Cerebrovasc Dis</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1934" to="1940" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Matsumoto K, Hanaoka S, Wu Y, Hasegawa T. Comprehensive cost of illness of three major diseases in Japan. J Stroke Cere- brovasc Dis. 2017;26:1934-40.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main" xml:id="_ADZJByq">Special Committee on Planning of Next National Health Promotion Campaign Health Sciences Council. Information material on the promotion of Health Japan</title>
		<idno type="DOI">10.1093/ww/9780199540884.013.u12940</idno>
		<ptr target="https://www.mhlw.go.jp/bunya/kenkou/dl/kenkounippon21_02.pdf" />
		<imprint>
			<date type="published" when="2012-07">July 2012</date>
			<biblScope unit="volume">21</biblScope>
		</imprint>
	</monogr>
	<note>Second edition</note>
	<note type="raw_reference">Special Committee on Planning of Next National Health Promo- tion Campaign Health Sciences Council. Information material on the promotion of Health Japan 21 (Second edition) (July 2012). https://www.mhlw.go.jp/bunya/kenkou/dl/kenkounippon21_02. pdf.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_bPFJSwW">The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Umemura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dohi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hirooka</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-019-0284-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zsxF7YC">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1235" to="1481" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235-481.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_veVZJsH">The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>She</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcph.559</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xHcsZWP">J Clin Pharm</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1362" to="1368" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang J, Qiu B, Du JL, Deng SB, Liu YJ, She Q. The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens. J Clin Pharm. 2015;55:1362-8.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_dqgJDAv">Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Weir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Chrysant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Mccarron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Canossa-Terris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gunter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hxxafdG">Hypertension</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1088" to="1096" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hyper- tensives. Hypertension 1998;31:1088-96.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_P3VqnaM">Physician and patient perspectives on hypertension management and factors associated with lifestyle modifications in Japan: results from an online survey</title>
		<author>
			<persName><forename type="first">N</forename><surname>Nishigaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shimasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hasebe</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-020-0398-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cAdwRjH">Hypertens Res</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="450" to="462" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nishigaki N, Shimasaki Y, Yoshida T, Hasebe N. Physician and patient perspectives on hypertension management and factors associated with lifestyle modifications in Japan: results from an online survey. Hypertens Res. 2020;43:450-62.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_EJ7YfbB">A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>So</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13993</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VstFTYm">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1713" to="1722" />
			<date type="published" when="2020">2020</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Nomura A, Harada N, Tanigawa T, So R, Nakagawa K, et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. J Clin Hypertens (Greenwich). 2020;22:1713-22.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_qZznfSJ">Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Okura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tanigawa</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehab559</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eJF82vx">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="4111" to="4122" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T, et al. Efficacy of a digital therapeutics system in the manage- ment of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J. 2021;42:4111-22.</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_GuEQYRX">Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gellings</forename><surname>Lowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jalali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1080/13696998.2020.1858581</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s9He4YF">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="61" to="68" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang W, Gellings Lowe N, Jalali A, Murphy SM. Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. J Med Econ 2021;24:61-68.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_grBJgEy">Cost-effectiveness analysis of a prescription digital therapeutic for the treatment of opioid use disorder</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Velez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Malone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4z4yNdW">J Mark Access Health Policy</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">1966187</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Velez FF, Malone DC. Cost-effectiveness analysis of a prescrip- tion digital therapeutic for the treatment of opioid use disorder. J Mark Access Health Policy. 2021;9:1966187.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_ZFUQWkq">Digital therapeutic care apps with decision-support interventions for people with low back pain in germany: cost-effectiveness analysis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lewkowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Wohlbrandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bottinger</surname></persName>
		</author>
		<idno type="DOI">10.2196/35042</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DhFZuKJ">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">35042</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lewkowicz D, Wohlbrandt AM, Bottinger E. Digital therapeutic care apps with decision-support interventions for people with low back pain in germany: cost-effectiveness analysis. JMIR Mhealth Uhealth. 2022;10:e35042.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_syhPJZU">Markov Models and Cost Effectiveness Analysis: Applications in Medical Research</title>
		<author>
			<persName><forename type="first">M</forename><surname>Komorowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Raffa</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-319-43742-2_24</idno>
		<ptr target="https://doi.org/10.1007/978-3-319-43742-2_24):Cham(CH" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_gqRUj9C">Secondary Analysis of Electronic Health Records</title>
		<imprint>
			<biblScope unit="page" from="351" to="367" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Komorowski M, Raffa J Markov Models and Cost Effectiveness Analysis: Applications in Medical Research. In: Secondary Ana- lysis of Electronic Health Records. https://doi.org/10.1007/978-3- 319-43742-2_24): Cham (CH), 2016, 351-67.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_KKMgPGy">Ministry of Internal Affiairs and Communications Statistics Bureau</title>
		<ptr target="https://www.stat.go.jp/english/data/nenkan/71nenkan/1431-02.html" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_sVkzSDf">Japan Statistical Yearbook</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note>Chapter 2-22 Life Table</note>
	<note type="raw_reference">Ministry of Internal Affiairs and Communications Statistics Bureau. Japan Statistical Yearbook 2022 (Chapter 2-22 Life Table). https://www.stat.go.jp/english/data/nenkan/71nenkan/ 1431-02.html.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_6Dh4f3d">Association of blood pressure classification using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kaneko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Itoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Morita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kiriyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kamon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uTVd758">Circulation</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="2244" to="2253" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, et al. Association of blood pressure classification using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation. Circulation. 2021;143:2244-53.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_5FpSJJg">In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: applicability of the GRACE risk score</title>
		<author>
			<persName><forename type="first">K</forename><surname>Komiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Niikura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Oikawa</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jjcc.2017.09.006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3jbhrvd">J Cardiol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="251" to="258" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, et al. In-hospital mortality analysis of Japanese patients with acute coronary syndrome using the Tokyo CCU Network database: applicability of the GRACE risk score. J Cardiol. 2018;71:251-8.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_Qx3ngpY">One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uchiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Origasa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kobayashi</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.cj-11-0378</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uwNc5H4">Circ J</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="2598" to="2604" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H, et al. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J. 2011;75:2598-604.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_PP4J6qY">9-year trend in the management of acute heart failure in japan: a report from the National consortium of acute heart failure registries</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Shiraishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kohsaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kitai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshikawa</surname></persName>
		</author>
		<idno type="DOI">10.1161/jaha.118.008687</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xZRGSnm">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">8687</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T, et al. 9-year trend in the management of acute heart failure in japan: a report from the National consortium of acute heart failure registries. J Am Heart Assoc. 2018;7:e008687.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_sYETQtf">Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sakata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nochioka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Onose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rXV4c6u">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1258" to="1269" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail. 2017;19:1258-69.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_YdVAFAQ">Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese-Shiga stroke registry</title>
		<author>
			<persName><forename type="first">N</forename><surname>Takashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Arima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Miyamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Komori</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.cj-17-0177</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qjTHzX9">Circ J</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1636" to="1646" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, et al. Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese-Shiga stroke registry. Circ J. 2017;81:1636-46.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_vGrtbPR">Lifetime risk of acute myocardial infarction in Japan</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Turin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kokubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Higashiyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rumana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Watanabe</surname></persName>
		</author>
		<idno type="DOI">10.1161/circoutcomes.109.930776</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HuMhVNP">Circ Cardiovasc Qual Outcomes</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="701" to="703" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, et al. Lifetime risk of acute myocardial infarction in Japan. Circ Cardiovasc Qual Outcomes. 2010;3:701-3.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_2ECmqHX">Hypertension and lifetime risk of stroke</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Turin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Afzal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rumana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Higashiyama</surname></persName>
		</author>
		<idno type="DOI">10.1097/hjh.0000000000000753</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_54ZjYND">J Hypertens</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="116" to="122" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Turin TC, Okamura T, Afzal AR, Rumana N, Watanabe M, Higashiyama A, et al. Hypertension and lifetime risk of stroke. J Hypertens. 2016;34:116-22.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_XY3paaf">Estimating incidence of acute heart failure syndromes in japan-an analysis from the KUNIUMI registry</title>
		<author>
			<persName><forename type="first">W</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Toh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takegami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kuroda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hatani</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.cj-20-1154</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WdK3Unj">Circ J</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="1860" to="1868" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fujimoto W, Toh R, Takegami M, Hayashi T, Kuroda K, Hatani Y, et al. Estimating incidence of acute heart failure syndromes in japan-an analysis from the KUNIUMI registry. Circ J. 2021;85:1860-8.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_qM56wPa">Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kamae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Koretsune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tanahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Murata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Phatak</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clinthera.2015.10.007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3T95BrH">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2837" to="2851" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, et al. Cost-effectiveness analysis of apixaban against warfarin for stroke prevention in patients with nonvalvular atrial fibrillation in Japan. Clin Ther. 2015;37:2837-51.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_n8faaZV">The impact of carperitide usage on the cost of hospitalization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mizuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Iguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sawada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hurley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayashi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2017.04.078</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PTxr6pk">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">241</biblScope>
			<biblScope unit="page" from="243" to="248" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mizuno A, Iguchi H, Sawada Y, Hurley M, Nomura H, Hayashi K, et al. The impact of carperitide usage on the cost of hospita- lization and outcome in patients with acute heart failure: High value care vs. low value care campaign in Japan. Int J Cardiol. 2017;241:243-8.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_NDfcTR8">Economic burden of arterial fibrillation in Japan (abstract)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kamae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kitamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sakurai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shibahara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Q9pcCQZ">Value Health</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">70</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kamae I, Kitamura A, Sakurai M, Yamamoto M, Inoue S, Shi- bahara H, et al. Economic burden of arterial fibrillation in Japan (abstract). Value Health. 2018;21:S70.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_cFnWaKJ">Costeffectiveness of percutaneous coronary intervention compared with medical therapy for ischemic heart disease in Japan</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kodera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kiyosue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Komuro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UwR98jN">Circ J</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1498" to="1505" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost- effectiveness of percutaneous coronary intervention compared with medical therapy for ischemic heart disease in Japan. Circ J. 2019;83:1498-505.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_fQRJ5Eq">Development of an official guideline for the economic evaluation of drugs/medical devices in Japan</title>
		<author>
			<persName><forename type="first">T</forename><surname>Shiroiwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fukuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Takura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Moriwaki</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2016.08.726</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_68TFDHa">Value Health</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="372" to="378" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K. Devel- opment of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health. 2017;20:372-8.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_myBY9PF">Medical care for chronicphase stroke in Japan</title>
		<author>
			<persName><forename type="first">N</forename><surname>Hattori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hirayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Katayama</surname></persName>
		</author>
		<idno type="DOI">10.2176/nmc.52.175</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_shYMy5w">Neurol Med Chir</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="175" to="180" />
			<date type="published" when="2012">2012</date>
			<pubPlace>Tokyo)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Hattori N, Hirayama T, Katayama Y. Medical care for chronic- phase stroke in Japan. Neurol Med Chir (Tokyo). 2012;52:175-80.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_PrhkMwv">Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Holman</surname></persName>
		</author>
		<idno type="DOI">10.1177/027298902400448902</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3uRHsUJ">Med Decis Mak</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="340" to="349" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak. 2002;22:340-9.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_absJ9BZ">Formal implementation of cost-effectiveness evaluations in japan: a unique health technology assessment system</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hasegawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Komoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shiroiwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fukuda</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2019.10.005</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7epQ2gP">Value Health</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="43" to="51" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal imple- mentation of cost-effectiveness evaluations in japan: a unique health technology assessment system. Value Health. 2020;23:43-51.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_8BSBPDY">Estimating the impact of novel digital therapeutics in type 2 diabetes and hypertension: health economic analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Nordyke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Appelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Berman</surname></persName>
		</author>
		<idno type="DOI">10.2196/15814</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zD49KQn">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">15814</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nordyke RJ, Appelbaum K, Berman MA. Estimating the impact of novel digital therapeutics in type 2 diabetes and hypertension: health economic analysis. J Med Internet Res. 2019;21:e15814.</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_vWdENuw">Achieving rapid blood pressure control with digital therapeutics: retrospective cohort and machine learning study</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Guthrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Berman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Appelbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carpenter</surname></persName>
		</author>
		<idno type="DOI">10.2196/13030</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jWMMeXu">JMIR Cardio</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">e13030</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Guthrie NL, Berman MA, Edwards KL, Appelbaum KJ, Dey S, Carpenter J, et al. Achieving rapid blood pressure control with digital therapeutics: retrospective cohort and machine learning study. JMIR Cardio. 2019;3:e13030.</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_X4TCv6Z">Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Rakugi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sasajima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gotou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41440-021-00819-7</idno>
		<ptr target="https://doi.org/10.1038/s41440-021-00819-7" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_v9tYf4W">Hypertens Res</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022. https://doi.org/10.1038/ s41440-021-00819-7.</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_dqbvAKy">Rates of attrition and dropout in app-based interventions for chronic disease: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Meyerowitz-Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ravi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arnolda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maberly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Astell-</forename><surname>Burt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<idno type="DOI">10.2196/20283</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9quPcAQ">J Med Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">e20283</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Meyerowitz-Katz G, Ravi S, Arnolda L, Feng X, Maberly G, Astell-Burt T. Rates of attrition and dropout in app-based inter- ventions for chronic disease: systematic review and meta-analysis. J Med Internet Res. 2020;22:e20283.</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_8TF6wFa">Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shimbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoshide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Asayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ohkubo</surname></persName>
		</author>
		<idno type="DOI">10.1161/HYPERTENSIONAHA.119.12630):HYPERTENSIONAHA11912630</idno>
		<ptr target="https://doi.org/10.1161/HYPERTENSIONAHA.119.12630):HYPERTENSIONAHA11912630" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_uZptJPA">Hypertension</title>
		<imprint>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Shimbo D, Hoshide S, Wang JG, Asayama K, Ohkubo T, et al. Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence. Hypertension. 2019. https://doi.org/10.1161/HYPERTENSIONAHA.119.12630): HYPERTENSIONAHA11912630.</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_Xh8Zxdn">State-of-the-Art review: home blood pressure monitoring: current status and new developments</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<idno type="DOI">10.1093/ajh/hpab017</idno>
		<ptr target="https://doi.org/10.1093/ajh/hpab017.e-pubaheadofprint20210209" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_k6BVBws">Am J Hypertens</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K. State-of-the-Art review: home blood pressure monitor- ing: current status and new developments. Am J Hypertens. 2021. https://doi.org/10.1093/ajh/hpab017. e-pub ahead of print 20210209</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_vyhvbzG">Consensus summary on the management of hypertension in Asia from the HOPE Asia Network</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kario</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sukonthasarn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Turana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shin</surname></persName>
		</author>
		<idno type="DOI">10.1111/jch.13917</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GXqGqS5">J Clin Hypertens</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="351" to="362" />
			<date type="published" when="2020">2020. 2020</date>
			<pubPlace>Greenwich)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Kario K, Park S, Chia YC, Sukonthasarn A, Turana Y, Shin J, et al. 2020 Consensus summary on the management of hyper- tension in Asia from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2020;22:351-62.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
